You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES
BACK TO ALL NEWS/

15-10-2014

New generation immunoglobulins: in January production of clinical batches

Construction of the new production line for NGIG clinical batches, Kedrion’s new generation 10% immunoglobulins, has been completed at the Gödöllő plant, one of the Kedrion’s production plants, located near Budapest in Hungary. The first batch of NGIG for the feasibility test was produced in early September and the analytical results were compliant with specifications. At the beginning of 2015, these lots will be used for the IND (Investigational New Drug), the request for registration of new products for clinical trials that must be submitted in the USA. To this end, the Gödöllő production plant will be subject to a mock inspection carried out by Kedrion aimed at assessing compliance with the quality standards of the American health authorities (FDA).
 

For more information please contact: investor@kedrion.com